Business

US President Trump’s plan for a “25% or higher” tariff on pharmaceuticals promises to have a far-reaching impact, from higher prices and drug shortages to increased onshoring of manufacturing in the US. Is MAGA worth the chaos it might create for MAHA? The Indian industry shares its views.

Boehringer Ingelheim’s sale of three diabetes brands in India, with the same composition as Jardiance, Jardiance Met and Glyxambi, to Torrent comes ahead of the expiry of the Indian patent for empagliflozin. A launch for other indications is also expected.

In Sept 2024, a new CMDO, DMX Pharma, emerged on the global market. Explore the benefits of this merger, from production capacity to cross-selling capability, regulatory expertise and their ambitious future plans.

Both companies are seeking to license their products as they try to stretch their dwindling cash.